IBC Life Sciences has been supporting and supplying the life science industry with specialized information through conferences and courses since 1987. IBC Life Sciences events offer attendees the opportunity to gain new insights and hear latest developments as well as provide a forum to meet, connect, and network. New Directions for Diabetes Therapeutics (16–17 February 2011): Hilton Boston Back Bay, Boston, MA Viral Safety for Biologicals (24–25 February 2011): Walt Disney World Swan Resort, Lake Buena Vista, FL AsiaTIDES (2–4…
Search Results for: antibody characterization
Protein Conjugates
Methods and Materials Thanks to vendors large and small — such as Invitrogen (www.invitrogen.com), ProteoChem (www.proteochem.com), Sigma Aldrich (www.sigmaaldrich.com), Soltec Ventures (www.soltecventures.com), and Thermo Scientific Pierce (www.piercenet.com) — bioconjugation chemistry is a field of many options. For example, amine coupling of lysine amino-acid residues typically involves amine-reactive succinimidyl esters. Sulfhydryl coupling of cysteine residues uses a sulfhydryl-reactive maleimide. Photochemically initiated free-radical reactions offer broader reactivity. Most processes couple small molecules to proteins or proteins to one another (e.g., antibodies…
Biopharmaceutical Development and Production Week
Join us for the week and you will Examine the latest scientific and technical advances to overcome the critical challenges faced by bioprocessing professionals at all stages of development to help you achieve your company’s process and product development goals. Find solutions to the unique challenges of developing and manufacturing therapeutic proteins, that will help you reduce time, cost, and variability during process and product development. Learn approaches to implement the latest analytical technologies that optimize process and product development.…
How to Choose an Industrial Cation Exchanger for IgG Purification
Cation-exchange chromatography is the third most used industrial method for antibody purification after anion-exchange and protein A affinity chromatography. It is most commonly used as an intermediate step but continues to attract attention as a capture method. This offers obvious cost and cleaning advantages over protein A but also imposes some sacrifices, all of which are discussed in a number of recent articles (1,2,3,4,5). Whichever application may be intended, end users seek a common set of performance characteristics.…
Formulation Effects on Opalescence of a High-Concentration MAb
Monoclonal antibodies (MAbs) are increasingly formulated at concentrations >100 mg/mL as a means to deliver a high dose in a low volume (1,2). Such high-concentration solutions are commonly opalescent (3,4), an undesirable characteristic of biopharmaceutical products for several reasons. Although it may be only aesthetic, opalescent products are not considered pharmaceutically “elegant.†Of more serious concern, opalescence may be a precursor to aggregation and indicate a propensity toward decreased product stability or quality. The term opalescent refers to…
Recovery and Purification
Downstream processing can be complex, expensive, and time-consuming part of biotherapeutics production. Biomanufacturers are seeking technologies to clear bottlenecks and incorporate rapid in-or at-line analytics. Data obtained from using these methods under a well established design space can then help companies better characterize, monitor, and control their processes. The BioProcess International Conference and Exhibition features a Recovery and Purification track over three days, 22–24 September 2010, that will cover these issues and provide attendees with the information needed…
Cell Culture and Production
Time to market, cost of goods, and reduction of financial risk are major challenges in protein manufacturing. Process intensification can help biotech companies achieve their goals. Already underway in several other industries, implementing this concept shrinks production facility sizes by 10–1,000 times using novel processes and products (e.g., single-use and isolator technologies in biotechnology) to reduce capital and operating costs. The results can be safer, more energy-efficient, and environmentally sustainable manufacturing processes. For example, Gerben Zijlstra (senior scientist…
Speeding Vaccine Development and Production
With infusions of public and private venture capital as well as technological advances, vaccine development is entering a new golden age as one of the fastest growing sectors in the biotechnology industry. In the 19th and 20th centuries, immunization programs eliminated or controlled infectious diseases including smallpox, polio, measles, mumps, and rubella. The biotech era has made significant changes both in the number of companies involved in vaccine manufacture and the production systems they use. BPI CONFERENCE SESSIONS…
Geographic Strategies in Biomanufacturing
In BPI’s June issue, we presented a supplement on geographical trends in biomanufacturing. We looked at the influence of a growing demand for biotherapeutics in emerging countries and the influence of new technologies that are driving interest in smaller, perhaps more geographically distributed production. We wanted to explore what a global bioeconomy would look like and where its primary capacity would be concentrated. Authors provided examples of how to balance cost with control issues. They talked about working in different…
Poster Presentations
Product Lifecycle Management Jayne Hesley, applications scientist in marketing for Molecular Devices, Inc. (Sunnyvale, CA) Homogeneous Antibody Binding Assay: Comparing Imaging Systems and Optimizing Acquisition Parameters for High-Throughput Screening Hybridoma cell lines are cultured to produce monoclonal antibodies for use in diagnostics, vaccine development, or therapeutics. One well-accepted assay for screening the antibody-containing supernatant of hybridomas is to capture the antibody on the surface of beads (